Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2019
May 20, 2019 at 04:22 pm
Share
Regenicin, Inc. announced earnings results for the second quarter ended March 31, 2019. For the second quarter, the company announced operating loss was USD 176,161 compared to USD 228,413 a year ago. Net loss was USD 178,351 compared to USD 233,266 a year ago. For the half year, operating loss was USD 415,153 compared to USD 431,452 a year ago. Net loss was USD 425,657 compared to USD 441,372 a year ago.
Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.